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and lipids, and may lead ultimately to cell death (Ryter 
et  al. 2007). The brain has a high metabolic rate, utilis-
ing twenty percent of the body’s total energy consump-
tion at rest (Magistretti pierre and Allaman 2015), yet it 
has a relatively poor antioxidant capacity (Katalinic et  al. 
2005); thus, it is unsurprising that the central nervous sys-
tem (CNS) is particularly sensitive to OS (Friedman 2011). 
Markers of OS are observed consistently in brain regions 
and cell populations affected by neurodegenerative dis-
ease, for example in Alzheimer’s disease (AD), Parkin-
son’s disease (PD) or amyotrophic lateral sclerosis (ALS) 
(Andersen 2004; Shukla et  al. 2011). However, it is still 
unclear whether disruption of the OS response is a direct 
cause of neurodegeneration in these disorders, or whether 
OS occurs as a result of neuronal dysfunction (Andersen 
2004; Ramanan and Saykin 2013).
Despite this debate, it has been long hypothesised that 
antioxidants may be valuable therapeutic targets applicable 
to neurological disease (Moreira et al. 2010). Consequently, 
the efficacy of neuroprotective intervention using small 
molecules with antioxidant properties has been tested—
with some success—in numerous rodent and primate mod-
els of AD, PD and ALS [reviewed in (Kamat et al. 2008)]. 
Translation of these antioxidant strategies in patients has 
been limited, however (Persson et al. 2014). An alternative 
but related therapeutic strategy has since been proposed, 
whereby the endogenous antioxidant mechanisms are har-
nessed to provide more biologically targeted protection in 
the CNS (Chan and Chan 2015). Consequently, it is critical 
to identify and characterise novel antioxidant proteins that 
are able to counteract damaging ROS in the brain. In this 
review, we will discuss recent evidence from genetic and 
molecular studies that the Tre2/Bub2/Cdc16 (TBC), lysin 
motif (LysM), domain catalytic (TLDc) domain-containing 
proteins are important players in the OS response and are 
Abstract Oxidative stress (OS) arises from an imbalance 
in the cellular redox state, which can lead to intracellular 
damage and ultimately cell death. OS occurs as a result of 
normal ageing, but it is also implicated as a common etio-
logical factor in neurological disease; thus identifying novel 
proteins that modulate the OS response may facilitate the 
design of new therapeutic approaches applicable to many 
disorders. In this review, we describe the recent progress 
that has been made using a range of genetic approaches to 
understand a family of proteins that share the highly con-
served TLDc domain. We highlight their shared ability to 
prevent OS-related cell death and their unique functional 
characteristics, as well as discussing their potential applica-
tion as new neuroprotective factors. Furthermore, with an 
increasing number of pathogenic mutations leading to epi-
lepsy and hearing loss being discovered in the TLDc pro-
tein TBC1D24, understanding the function of this family 
has important implications for a range of inherited neuro-
logical diseases.
Introduction
The oxidative stress (OS) response is an essential cellular 
process that is required to maintain the physiological levels 
of reactive oxygen species (ROS), by-products of oxygen 
metabolism. ROS are essential intracellular messengers 
(Rhee 2006; Sauer et  al. 2001), although any imbalance 
in the levels of ROS can cause damage to DNA, proteins 
 * Peter L. Oliver 
 peter.oliver@dpag.ox.ac.uk
1 Department of Physiology, Anatomy and Genetics, 
University of Oxford, Parks Road, Oxford OX1 3PT, UK
396 M. J. Finelli, P. L. Oliver 
1 3
therefore potential therapeutic targets applicable to many 
neurological and neurodegenerative disorders.
The TLDc domain is a highly conserved protein motif 
present in several mammal proteins that share a protec-
tive function against OS: nuclear receptor coactivator 7 
(NCOA7 or TLDC4), oxidation resistance 1 (OXR1 or 
TLDC3), TBC1 domain family member 24 (TBC1D24 
or TLDC6), TBC/LysM-associated domain containing 
1 (KIAA1609 or TLDC1) and TBC/LysM-associated 
domain containing 2 (C20ORF118 or TLDC2) (Fig.  1) 
(Finelli et al. 2016). The most evolutionary distant protein, 
TLDC5, or interferon-induced protein 44 (IFI44; protein 
accession number NP_006408), contains a putative TLDc 
domain with only 15% amino acid identity to the other 
members. Evidence that the TLDc domain is essential to 
normal human brain development and function has been 
highlighted recently by the identification of mutations in 
the TLDc domain of TBC1D24 in patients with myoclonic, 
focal or generalized epilepsy, DOORS (deafness, onychod-
ystrophy, osteodystrophy, mental retardation and seizures) 
syndrome and lethal early-onset epileptic encephalopathy 
(Balestrini et  al. 2016; Campeau et  al. 2014a, b; Mucha 
et al. 2015). Therefore, understanding the molecular mech-
anisms that underlie the function of the TLDc domain will 
shed light on the OS response and its involvement in a wide 
range of neurological diseases.
Oxidation resistance gene 1 (OXR1)
OXR1 is protective against oxidative stress
OXR1 was first identified in a human cDNA library screen 
for genes that were able to rescue the DNA oxidation 
repair-defective phenotype of a spontaneous E.coli mutant 
(Volkert et al. 2000). This apparent OS-related function of 
OXR1 was shown to be evolutionary conserved in eukar-
yotes: the yeast strain S. cerevisiae with deletion of the 
homologue scOxr1 was more sensitive to hydrogen per-
oxide  (H2O2) treatment than controls (Volkert et al. 2000), 
and this phenotype could be rescued by expressing human 
OXR1 targeted to the mitochondria (Elliott and Volkert 
2004).
Oxr1 has also been shown to be essential for CNS func-
tion in mammals. Bella mouse mutants, which harbour a 
homozygous spontaneous deletion spanning the entire cod-
ing sequence of Oxr1, display degeneration in the cerebel-
lar granule cell layer from postnatal day (P)18, followed by 
rapidly progressive ataxia and death by P24 (Oliver et  al. 
2011). This dramatic phenotype was fully rescued by ubiq-
uitous expression of an Oxr1 transgene, confirming that the 
phenotype of the bella mutant is caused by loss of the gene 
(Oliver et al. 2011). Significantly, a new insertional mouse 
mutant in which the last 101 amino acids of the TLDc 
domain of Oxr1 is removed has an essentially identical 
phenotype to the bella Oxr1 deletion mouse, demonstrat-
ing the importance of the TLDc domain for the function of 
the protein (Finelli et  al. 2016; Oliver et  al. 2011). These 
particular findings are in line with in vitro studies demon-
strating that the shortest Oxr1 isoform, containing almost 
Fig. 1  Domain architecture of mammalian TLDc proteins. 
Domains marked as TLDc: Tre2/Bub2/Cdc16 (TBC), Lysin 
Motif (LysM), Domain Catalytic; LysM: lysin motif; GRAM: 
GRAM domain; ERbd: estrogen receptor binding domain; Rab-
GAP: GTPase activating protein; EF-hand: EF-hand domain; N-M: 
N-myristoylation domain. The accession numbers correspond-
ing to the human isoforms as shown are: OXR1 (NP_001185461), 
OXR1-C (NP_001185464), NCOA7 (NP_001186548), NCOA7-
B (NP_001186551), TBC1D24 (NP_001186036), KIAA1609 
(NP_065998) and C20ORF118 (NP_001291712). The unique first 
coding exons of NCOA7-B and OXR1-C are shown in dark grey and 
the position of a premature stop codon mutation identified in OXR1-
C in specific language impairment is marked with an asterisk (Chen 
et al. 2017)
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exclusively the TLDc domain (Fig. 1), is as potent an anti-
oxidant as the full-length protein (Finelli et al. 2016; Oliver 
et al. 2011).
Consistent with the original findings in bacteria that 
over-expressing OXR1 is protective against OS, an increase 
in OXR1 levels has a similar effect in a wide range of mam-
malian cell types (Finelli et  al. 2016; Murray et  al. 2013; 
Yang et al. 2014). Furthermore, this protective function has 
been established in other genetic systems. For example, 
Drosophila embryos reared on an OS-inducing  H2O2 solu-
tion are more likely to survive as adults when injected with 
Oxr1 from the silk moth Bombyx mori (bm), and bmOxr1 
also significantly increases the 50% survival time of Dros-
ophila reared on a control diet by 11% (Kobayashi et  al. 
2014). Although this particular finding has not been repli-
cated in other invertebrate models, these data suggest that 
Oxr1 is beneficial for survival, both under induced OS and 
physiological conditions.
To investigate whether Oxr1 could be similarly protec-
tive in a mammalian genetic model, a mouse over-express-
ing Oxr1 specifically in neurons was crossed with the 
well-characterised superoxide dismutase 1  (hSOD1G93A) 
mouse model of ALS (Gurney et al. 1994; Liu et al. 2015). 
Increasing Oxr1 levels in  hSOD1G93A mice not only delayed 
the expression of OS-related markers in the spinal cord, but 
it also improved motor neuron survival, motor coordination 
and life-span (Liu et al. 2015). Interestingly, Oxr1 binds to 
two other proteins that are associated with familial forms 
of ALS, TAR DNA-binding protein 43 (TDP-43) and fused 
in sarcoma (FUS) (Finelli et al. 2015). In vitro co-expres-
sion of Oxr1 with TDP-43 and FUS showed that disease-
causing mutations could influence the binding affinity to 
Oxr1, which in-turn was associated with a reduction in the 
aberrant cellular features associated with these mutants 
(Finelli et al. 2015). It was also observed that the interme-
diate TLDc-domain-containing OXR1 isoforms were up-
regulated compared to age-matched controls in end-stage 
post-mortem spinal cord from patients with ALS, as well as 
a threefold increase in the full-length Oxr1 in spinal cords 
of pre-symptomatic  hSOD1G93A mice (Oliver et al. 2011). 
Together, these studies propose that OXR1 plays an impor-
tant role in ALS-associated pathogenesis, and could even 
be a valuable therapeutic target for neurodegenerative dis-
orders susceptible to OS.
OXR1: functional hypotheses
It has been hypothesised that OXR1 might function by 
reacting directly with ROS (Finelli et  al. 2016; Oliver 
et al. 2011; Sanada et al. 2014; Yang et al. 2014), similar 
to antioxidant enzymes such as SOD1 (McCord and Fri-
dovich 1969) or glutathione reductase (Massey and Wil-
liams 1965). Indeed, over-expression of OXR1 can reduce 
superoxide (Finelli et  al. 2016) or  H2O2 levels in  vitro 
(Yang et  al. 2014); however, to date, there is no evidence 
for an enzymatic activity of OXR1 or the TLDc domain. 
In fact, the oxidation of reactive cysteine residues in 
OXR1 does not occur in the catalytic range (Oliver et  al. 
2011) and the protein does not demonstrate any catalase or 
superoxide dismutase activity (Sanada et  al. 2014). Alter-
natively, OXR1 could influence OS response pathways 
indirectly by modulating the activity of effector proteins. 
Indeed, an in silico pathway analysis performed on Oxr1 
binding partners identified by co-immunoprecipitation in 
neuronal cells suggested that Oxr1 interacts with proteins 
involved in mTOR and EIF2 pathways (Finelli et al. 2015), 
key regulatory elements of the OS response (Maiese et al. 
2012; Ron and Harding 2007; Teske et al. 2011). Another 
possible functional role of OXR1 is a more direct influ-
ence on the activity of known cellular antioxidants. In the 
mosquito Anopheles cambiae (A. cambiae), silencing the 
homologue of OXR1 significantly decreases the expres-
sion of both catalase and glutathione peroxidase (Gpx) by 
92 and 82%, respectively. Moreover, chemically inhibiting 
the JNK pathway in larval Bombyx mori reduced Oxr1 lev-
els in this organism (Su et  al. 2016). Similarly, silencing 
Jun N-terminal kinase (JNK), a gene normally activated by 
stress, leads to a decrease in Oxr1 expression in mosquitoes 
(Jaramillo-Gutierrez et  al. 2010). This suggests a detoxi-
fying cascade arising from JNK, regulating OXR1 tran-
scription, which in turn induces expression of antioxidant 
enzymes (Jaramillo-Gutierrez et al. 2010, Su et al. 2016); 
thus, OXR1 may act downstream of the JNK pathway to 
regulate the OS response. Interestingly, a study describing 
the interactome of the proton V-ATPase pump identified 
Oxr1 and Ncoa7 as potential binding partners in the kidney 
(Merkulova et  al. 2015). A functional link between vacu-
olar acidification and OS has been demonstrated in yeast 
(Milgrom et al. 2007); this would suggest another potential 
mechanism of regulation of OS by OXR1 through modu-
lation of V-ATPase activity or stability of the V-ATPase 
complex.
Next, to dissect the pathway(s) downstream of OXR1 in 
more detail, transcriptomic analysis was carried out in the 
human cervical cancer (HeLa) cell line in which the level 
of OXR1 was knocked-down by 85% (Yang et  al. 2015, 
2014). More than 600 genes were differentially expressed 
in untreated OXR1-depleted cells compared to wild-type 
cells, with around half of these genes being similarly regu-
lated in untreated or  H2O2-treated conditions (Yang et  al. 
2015). Interestingly, the expression of several antioxidant 
genes, such as heme oxygenase (HO-1) and cyclin-depend-
ent kinase inhibitor 1 (p21), was reduced in OXR1-depleted 
cells, both in untreated and treated conditions (Yang et al. 
2015, 2014). Together with the data from knockdown stud-
ies in the mosquito, these studies suggest that Oxr1 can 
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modulate, either directly or indirectly, the expression of 
ROS-reducing enzymes.
Gene ontology analysis of the differentially expressed 
genes in OXR1-depleted HeLa cells identified the p53 path-
way as most significantly altered (Yang et al. 2015); these 
data therefore implicate OXR1 in cell-cycle progression 
and apoptosis via p53 and transcription of its target genes 
(Yang et al. 2015, 2014). However, given the importance of 
p53 in cancer cell physiology (Muller and Vousden 2014), 
it would be interesting to carry out a transcriptomic study 
in non-immortalised cell line to assess the relevance of this 
observation in a physiological context. At present, one can 
only speculate that OXR1 might modulate the transcrip-
tion of p53-target genes by binding to p53 in the cytoplasm, 
modifying p53 activity or localisation, and facilitating the 
transcription of p53 target genes (Yang et  al. 2015). This 
study also suggested a wider role for OXR1, in particular 
through the regulation of an array of essential transcrip-
tion factors such as E2F transcription factor 8 (E2F8) and 
transcription factor 3 (TCF3) (Yang et al. 2015). However, 
how OXR1 would regulate the expression of these genes, 
both in non-treated and oxidative stress conditions, remains 
to be explored. There is some evidence for nucleolar and 
nuclear expression for OXR1 and the Drosophila OXR1 
homologue mustard (mtd, see below) in  vivo that would 
suggest a role in transcription (Fischer et  al. 2001; Natoli 
et  al. 2008; Wang et  al. 2012). Indeed, NCOA7 has been 
shown to be nuclear localised and is implicated in tran-
scriptional regulation (Arai et al. 2008; Durand et al. 2007; 
Paramanik and Thakur 2010; Shao et al. 2002); yet further 
studies are required to determine how OXR1 may influence 
transcription and whether this occurs by either a direct or 
indirect mechanism.
OXR1 in infection and the immune response
In addition to its well-studied role in regulating OS sensi-
tivity, OXR1 has been implicated in the response to bacte-
rial infection. In a forward-genetic screen to identify host 
factors reducing proliferation of the parasite Plasmodium 
gallinaceum, a loss-of-function Drosophila mutant in the 
l(3)82Fd gene corresponding to the OXR1 homologue 
was identified, which presented a fivefold reduction in the 
number of mature oocytes of the parasite compared to the 
fly control line (Brandt et  al. 2008). In addition, a gain-
of-function mutant with an insertion in the same locus, 
renamed mtd, showed an increased tolerance to oral Vibrio 
cholerae infection mediated by the innate immune response 
(Wang et  al. 2012). The mutant mtd phenotype could be 
mimicked by over-expressing a short mtd transcript con-
taining only the TLDc domain, demonstrating that this 
region was important for sensitivity to infection (Wang 
et  al. 2012). Consistent with this finding in Drosophila, 
knockdown of the A. gambiae OXR1 homologue resulted 
in a significant decrease in the Plasmodium berghei load in 
mosquitoes (Jaramillo-Gutierrez et al. 2009). As it has been 
observed previously that systemic ROS levels can influence 
Plasmodium berghei infection (Molina-Cruz et al. 2008), it 
was hypothesised that the lower rate of infection in A. gam-
biae following OXR1 silencing was due to the decrease in 
expression of ROS-clearing enzymes (Jaramillo-Gutierrez 
et  al. 2010). However, the levels of ROS have not been 
assessed in this model system to confirm this hypothesis.
Supporting a potential role for OXR1 in the immune 
response in mammalian systems, mouse strains resist-
ant to inflammation of the kidneys express significantly 
higher levels of Oxr1 than more sensitive strains (Li 2014). 
Subsequently, OXR1 was tested as a therapeutic target in 
a mouse model for an autoimmune disease caused by sys-
temic lupus erythematosus (Li 2014). Mesenchymal stem 
cells (MSC) expressing OXR1 were delivered intrave-
nously to these mice, leading to successful implantation in 
their kidneys. This resulted in the reduction of abnormal 
serum and urine nitric oxide levels, inhibition of cytokine 
and interleukin up-regulation, and a decrease in T-lympho-
cyte and macrophage infiltration into the kidneys (Li 2014). 
Somewhat related results were obtained in the  hSOD1G93A 
ALS model, where a reduction in the expression of several 
neuroinflammatory and complement activating markers 
occurred in SOD1 mutants over-expressing Oxr1 (Liu et al. 
2015); this in turn led to decreased astrogliosis and micro-
gliosis in spinal cord of  hSOD1G93A mice (Liu et al. 2015). 
Given the established links between inflammation, comple-
ment activation and neurodegeneration (Cappellano et  al. 
2013), it will be essential to investigate further how OXR1 
is able to modulate the immune response and if this is a key 
feature of its neuroprotective properties.
TBC1 domain family member 24 (TBC1D24)
TBC1D24 is mutated in a range of human genetic 
disorders of the nervous system
The importance of TBC1D24 in normal brain function 
was first demonstrated by the identification of mutations 
in patients with various forms of epilepsy (Corbett et  al. 
2010; Falace et al. 2010). Indeed, this finding was the first 
genetic cause of human epilepsy to be discovered by exome 
sequencing. Since then, over 30 combinations of compound 
heterozygous or homozygous mutations in TBC1D24 have 
been reported, spanning almost the entire coding sequence 
(Campeau 2016). These mutations cause a surprisingly 
broad range of disorders, including familial infantile myo-
clonic epilepsy (Falace et  al. 2010; Poulat et  al. 2015), 
early onset progressive encephalopathy associated with 
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myoclonic epilepsy with severe cerebral neurodegenera-
tion (Guven and Tolun 2013), familial malignant migrating 
partial seizures of infancy (Milh et al. 2013), early infantile 
epileptic encephalopathy (Stražišar 2015), lethal neonatal 
seizure disorder (Lozano et al. 2016), focal epilepsy associ-
ated with intellectual disability (Corbett et al. 2010), mul-
tifocal myoclonus with cerebellar dysfunction (Doummar 
2015), focal epilepsy associated with developmental delays 
and head growth deceleration (Appavu et  al. 2016). Most 
recently the disease spectrum has expanded to include 
multifocal polymyoclonus with neurodevelopmental delay 
(Ngoh et  al. 2017) and alternating hemiplegia with recur-
rent episodes of epilepsia partialis continua (Ragona et al. 
2017). Mutations in TBC1D24 are also associated with 
DOORS syndrome, a rare disorder characterised by hearing 
loss and shortened terminal phalanges with small nails of 
the hands and feet, in addition to seizures and neurodevel-
opmental delay (Campeau et  al. 2014b). TBC1D24 muta-
tions have been identified in approximately half of those 
diagnosed with DOORS syndrome to date; thus, there are 
likely to be other causative genetic factors as well as poten-
tial clinical overlap with disorders such as Coffin-Siris 
syndrome that share many, if not all, of the cardinal fea-
tures of DOORS (Campeau et  al. 2014a, b). This disease 
association is particularly interesting as patients with com-
pound heterozygous TBC1D24 mutations can also present 
with hearing loss associated with an early-onset epilep-
tic encephalopathy (Stražišar 2015); furthermore, domi-
nant (Azaiez et al. 2014; Zhang et al. 2014) and recessive 
(Rehman Atteeq et al. 2014) TBC1D24 mutations can also 
cause non-syndromic hearing impairment, with no reported 
epileptic phenotype (Azaiez et  al. 2014; Rehman Atteeq 
et al. 2014; Zhang et al. 2014). Consistent with the range of 
pathologies described in patients carrying TBC1D24 muta-
tions, Tbc1d24 is expressed in the early embryonic brain 
as well as in the inner and outer hair cells and in the spi-
ral ganglion neurons in rodents (Falace et al. 2010; Finelli 
et al. 2016; Rehman Atteeq et al. 2014; Zhang et al. 2014).
By compiling the epilepsy and DOORS-associated 
TBC1D24 mutations detected to date with their corre-
sponding clinical features, there is some evidence that the 
more severe clinical phenotypes are associated with non-
sense, frameshift or splice-site mutations (Balestrini et al. 
2016). TBC1D24 protein levels have also been shown 
to be significantly decreased in fibroblasts from patients 
possessing compound heterozygous mutations (Campeau 
et  al. 2014b; Lozano et  al. 2016). These particular data 
are limited to non-CNS cultured cells for a small propor-
tion of TBC1D24 mutations, but they do suggest that the 
range of disease phenotypes may result from a variable loss 
of TBC1D24 expression (Campeau et  al. 2014b; Lozano 
et  al. 2016). To establish whether the diversity of pheno-
types observed can be explained by a particular threshold 
of TBC1D24 protein stability, it would be essential to carry 
out a more systematic study of protein expression in equiv-
alent experimental samples from a full range of disease 
cases. Such a dataset will help to determine whether the 
majority of cases are defined by a loss-of-function mecha-
nism, or whether gain-of-function modes of action need 
to be considered further. Significantly, it has been shown 
recently that siblings with the same compound heterozy-
gous missense variants can present different disease sever-
ity and progression (Lozano et  al. 2016). Although these 
particular individuals are non-identical twins, this finding 
does suggest that both genetic and non-genetic components 
determine the presentation of TBC1D24-associated dis-
eases (Lozano et al. 2016). Thus, despite the obvious plei-
otropic effects of this gene, these recent studies highlight 
the complexity in establishing a direct correlation between 
genotype and phenotype in TBC1D24-associated disorders 
(Balestrini et al. 2016).
TBC1D24 in neuronal migration, differentiation 
and vesicle trafficking
Epilepsy is characterised by spontaneous neuronal activ-
ity that often arises from defects in neuronal development, 
migration or synaptic transmission (Bozzi et  al. 2012); 
therefore, the role of TBC1D24 in these specific processes 
has been assessed both in vitro and in vivo. Over-expres-
sion of wild-type Tbc1d24 in mouse cortical or hippocam-
pal neurons enhances greatly axonal outgrowth and branch-
ing, while expressing disease-causing amino-acid changes 
in either the TLDc or TBC domain of TBC1D24 negates 
this axon growth phenotype (Balestrini et al. 2016; Corbett 
et  al. 2010; Falace et  al. 2010; Milh et  al. 2013). Impor-
tantly, knock-down of Tbc1d24 expression in rat primary 
cortical neurons also stunted neurite outgrowth (Falace 
et al. 2014); this apparent delay of neuronal maturation led 
to functional abnormalities in these knockdown neurons, 
including a reduced frequency and amplitude of excita-
tory postsynaptic currents (Falace et al. 2014). In addition, 
reducing Tbc1d24 levels in neuronal progenitor cells of 
embryonic rat brain resulted in a defective radial migra-
tion and morphological maturation of pyramidal neurons, 
with reduction of their arborisation and transition from 
multipolar to bipolar neurons (Falace et  al. 2014). These 
data demonstrate a critical role for TBC1D24 in regulating 
neuronal differentiation and are crucial when dissecting the 
possible mechanisms underlying TBC1D24-associated epi-
lepsy. Indeed, given that pathogenic mutations may result 
in reduced protein levels (Campeau et  al. 2014b; Lozano 
et al. 2016; Milh et al. 2013), it is possible—although not 
yet demonstrated—that glutamatergic neurons in patients 
are not fully differentiated and are unable to stimulate the 
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inhibitory interneurons, leading to an imbalance of the 
excitatory and inhibitory signals (Bozzi et al. 2012).
TBC1D24 has also been shown to play a key role in 
neurotransmission. Indeed, the TBC1D24 C.elegans hom-
ologue, C31H2.1, was identified originally in an RNAi 
screen for genes that modulate the release of neurotrans-
mitter acetylcholine at the neuromuscular junctions (NMJ) 
(Sieburth et  al. 2005). In a more recent screen for genes 
affecting synaptic transmission in Drosophila, an allelic 
series of mutants in the Skywalker (sky) TBC1D24 ortho-
logue were characterised. A reduction in sky expression by 
more than 75% of control levels led to an increased num-
ber of synaptic vesicles and increased neurotransmission at 
the NMJ of Drosophila larvae (Uytterhoeven et  al. 2011; 
Verstreken et al. 2009). This phenotype was linked to per-
turbed endo-lysosomal sorting, an overly efficient degrada-
tion of ubiquitinated proteins, and larger readily releasable 
vesicles; it was proposed that the resulting effects on neu-
rotransmission might relate to aberrant neuronal activity 
observed in human seizures (Uytterhoeven et al. 2011).
In addition to the TLDc domain, TBC1D24 harbours 
a TBC domain, which is found in the majority of Rab-
GTPase activating proteins (RabGAPs) (Frasa et  al. 
2012). Importantly, the TBC domain present in human 
TBC1D24 lacks the typical arginine ‘finger’ required 
for GAP activity and activation of Rab GTPases (Cor-
bett et al. 2010; Fischer et al. 2016). Similar to the TBC 
proteins TRE17 and TBC1D3, that also lack the same 
critical arginine, TBC1D24 binds the small GTPase ADP 
ribosylation factor 6 (ARF6) (Frittoli et  al. 2008; Mar-
tinu et  al. 2004) and it inhibits the formation of active 
ARF6-GTP (Falace et al. 2014, 2010). ARF6 plays many 
important roles in synaptic vesicle trafficking (Fassio 
et al. 2016; Frittoli et al. 2008; Tagliatti et al. 2016), cell 
migration stimulation and cell guidance (Akiyama and 
Kanaho 2015; Santy and Casanova 2001), as well as neu-
rite outgrowth and dendritic spine maturation (Alberti-
nazzi et al. 2003; Choi et al. 2006; Miyazaki et al. 2005). 
As many TBC1D24 pathogenic variants identified in 
patients are located in the TBC domain, this suggests 
that TBC1D24 function may rely, at least partially, on 
an interaction with ARF6. Indeed, inactive ARF6-GDP 
rescued the radial migration defects observed in vivo that 
are associated with Tbc1d24 knockdown (Falace et  al. 
2014), while electroporation of active ARF6-GTP pheno-
copied a reduction in Tbc1d24 expression (Falace et  al. 
2014). Together, these data support the hypothesis that 
TBC1D24 plays a key role in synaptic transmission via 
regulation of ARF6 activation. It is likely that, in addi-
tion to ARF6, other GTPases are a feature of TBC1D24 
function at the synapse. Indeed, it has been shown that 
TBC1D24 can also inactivate Rab35 (Uytterhoeven et al. 
2011) and that Arf6 and Rab35 can inhibit each other by 
recruitment of reciprocal GAPs (Chaineau et  al. 2013; 
Dutta and Donaldson 2015). Therefore, it is possible that 
the ratio of active to inactive forms of Rab35 and Arf6 
are critical to regulate TBC1D24-associated synaptic 
function.
It is noteworthy that mouse hippocampal neurons lack-
ing Arf6 demonstrate an accumulation of endosomal 
structures at the synapse upon stimulation, similar to the 
synaptic phenotype observed in Drosophila neurons with 
reduced sky levels (Tagliatti et  al. 2016; Uytterhoeven 
et  al. 2011). However, this apparently related synaptic 
phenotype was suggested to have arisen by different path-
ways in the two studies: loss of Arf6 leads to an apparent 
deficiency in vesicle formation upon stimulation (Tagli-
atti et al. 2016), while loss of sky leads to an increase in 
synaptic vesicle trafficking via the intermediate endoso-
mal compartment and defect in vesicle recycling (Uyt-
terhoeven et  al. 2011). These experiments indicate that 
although TBC1D24 and ARF6 are able to modulate 
vesicle trafficking, their functional relationship in dis-
ease is more complex than simply the aberrant activation 
of ARF6 due to loss-of-function TBC1D24 mutations. 
Therefore, further studies are required to ascertain the 
in  vivo functional significance of the TBC1D24:ARF6 
interaction, particularly in the light of such a wide array 
of pathogenic TBC1D24 mutations documented to date.
While functional studies have focused on the role of 
TBC1D24 at the synapse, it must also be considered 
that TBC1D24 confers neuronal resistance against OS 
via its TLDc domain (Finelli et  al. 2016); for example, 
epilepsy-associated mutations appear to be detrimental to 
OS resistance in neurons (Finelli et al. 2016). These data 
are also consistent with the modulation of an epileptic 
phenotype. Indeed, hallmarks of OS-dependent damage, 
such as lipid peroxidation of erythrocyte membrane, are 
observed in epileptic patients (Sudha et al. 2001). It has 
also been proposed that an increase in OS leads to synap-
tic dysfunction, neuronal hyperactivity and neuronal loss 
[reviewed in (Aguiar 2012; Chang and Yu 2010)]. Simi-
larly, OS is proposed to play a central role in hearing loss, 
in particular age-related forms (Fujimoto and Yamasoba 
2014); although it is unknown at present whether hearing 
loss-associated mutations affect the antioxidative func-
tion of TBC1D24. For example, as Tbc1d24 is expressed 
at a specific early postnatal time period (before P7) dur-
ing development of the hair cells in the inner ear of the 
mouse, it will be important to investigate whether this 
confers protection against OS-associated insults (Azaiez 
et  al. 2014; Rehman Atteeq et  al. 2014; Zhang et  al. 
2014). In summary, the complex and pleiotropic effects 
of TBC1D24 will have to be considered when design-
ing future therapeutic strategies for TBC1D24-associated 
disorders.
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Nuclear receptor coactivator 7 (NCOA7)
NCOA7 is a nuclear receptor coregulator modulating 
gene transcription
NCOA7, originally identified as estrogen receptor-associ-
ated protein 140 (ERAP140) (Shao et  al. 2002), contains 
a putative estrogen receptor-binding domain that had also 
been identified in ERAP160, a proven estrogen receptor 
alpha (ERα) interactor (Halachmi et  al. 1994). Similarly, 
NCOA7 interacts with ERα and with an array of nuclear 
receptors such as ERβ1, ERβ2, the ligand-activated tran-
scription factor arylhydrocarbon receptor (AhR) and its 
nuclear transporter (Arnt) (Arai et  al. 2008; Cho et  al. 
2015; Paramanik and Thakur 2010), as well as other 
coregulators such as NCOA3 (Lanz et  al. 2010). Bind-
ing of NCOA7 to its target nuclear receptors modulates 
their transcriptional activity, which suggests that NCOA7 
acts as a transcriptional coregulator (Arai et  al. 2008; 
Cho et al. 2015; Nguyen 1999; Shao et al. 2002). Nuclear 
receptor coregulators are essential rate-limiting intermedi-
ates between nuclear receptors and the general transcrip-
tional machinery, influencing fundamental processes in 
the nervous system (Tetel and Acharya 2013). For exam-
ple, Ncoa7 enhances the binding of the aryl hydrocarbon 
receptor (AhR/Arnt) complex to the dioxin response ele-
ment of AhR/Arnt target genes under dioxin and estradiol 
exposure (Cho et al. 2015; Nguyen 1999; Xie et al. 2016). 
In addition, chromatin immunoprecipitation revealed that 
NCOA7, when bound to ERα or Ahr, associates with the 
promoter of their target genes, pS2 and cyclin D1, respec-
tively, inducing their expression (Shao et  al. 2002; Xie 
et  al. 2016). Moreover, the expression of NCOA7 can be 
regulated by nuclear receptor ligands themselves; for 
instance, 1.0 nM androgen significantly reduces the expres-
sion of NCOA7 by 40% in prostate cancer cells (Heem-
ers et  al. 2009). However, the functional significance of 
NCOA7 to genome-wide transcriptional regulation is not 
known, in particular when compared to well-characterised 
nuclear coregulators such as steroid receptor coactivator 1 
(SRC-1) (Walsh et al. 2012). Furthermore, as Ncoa7 can be 
highly protective against OS in vitro (Finelli et al. 2016; Yu 
et al. 2015), it is also possible that the protein regulates the 
expression of antioxidant enzymes, although this phenom-
enon is unlikely to involve the shortest isoforms as it lacks 
the nuclear localisation sequence or putative ER-binding 
domain of the full-length protein (Fig. 1).
Additional potential functions of NCOA7
Whether NCOA7 plays a direct role in human disease 
is still unclear. However, NCOA7 expression is sig-
nificantly induced by twofold in models of Rhinovirus 
infection (Baines et  al. 2013), by almost threefold in bac-
terial lipopolysaccharides (LPS)-activated macrophages 
(Alasoo et al. 2015) or by twofold in LPS-activated mono-
cytes (Schirmer 2008), which suggests a role for Ncoa7 in 
the immune response. In addition, NCOA7 has been con-
sistently identified as highly induced by interferons (IFNs), 
which are potent cytokines used to treat a wide variety 
of diseases [reviewed in (González-Navajas et  al. 2012)]. 
Treatment with an array of IFNs, for example IFNα in 
malignant melanoma (Zimmerer et al. 2008) or IFNα2b for 
chronic hepatitis C infection (Honda et  al. 2010), induces 
the expression of NCOA7; although the specific isoforms 
involved in these studies were not reported. A more recent 
study has highlighted the importance of distinguishing 
these NCOA7 isoforms; in peripheral blood mononuclear 
cells from multiple sclerosis patients treated with IFNβ1b, 
a unique short NCOA7 isoform was significantly induced 
by more than 60-fold only 4 h post-IFNβ1b treatment (Yu 
et al. 2015). Interestingly, this specific isoform is induced 
by LPS but not OS, suggesting a specific role for this iso-
form as part of an immune response (Yu et  al. 2015). In 
addition to its role in inflammation, IFN is implicated in 
the OS response via the transcriptional regulation of anti-
oxidant genes (Croze et al. 2013; Lucas et al. 2003); thus, it 
is possible that NCOA7 may be a downstream regulator of 
IFN, directly or indirectly regulating the immune response 
and OS response.
TBC/LysM‑associated domain containing 1 
(KIAA1609)
The C.elegans eak-7 gene was first discovered as part of a 
screen for genes regulating DAF-16/FOXO, both key tran-
scription factors promoting life span extension and stress 
resistance (Alam et  al. 2010). Because Eak7 encodes a 
protein with a consensus N-myristoylation motif and a 
TLDc domain, it was suggested to be a putative orthologue 
of KIAA1609 (Moriya et  al. 2013; Williams et  al. 2010). 
Eak-7 inhibits activity of the transcription factor Daf-16, 
ultimately reducing the expression of specific target genes 
(Alam et al. 2010). Eak-7 null mutants showed an enhance-
ment in the duration of the quiescent physiological larval 
stage and in their lifespan; this phenotype being reverted 
by neuronal-specific expression of eak-7 (Alam et  al. 
2010). The N-myristoylation domain in eak-7 facilitates its 
localisation to the plasma membrane; however, preventing 
N-myristoylation does not disrupt completely eak-7 func-
tion (Alam et al. 2010); thus, localisation to the membrane 
is not an absolute requirement.
The potential involvement of KIAA1609 in the OS 
response has also been tested; however, conflicting 
results have been observed in C.elegans and mamma-
lian cells. Indeed, eak-7 null mutants in C.elegans present 
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an increased survival after exposure to  H2O2 (Alam et  al. 
2010), while Kiaa1609 silencing in mammalian neu-
ronal cell line treated with arsenite, an OS-induced agent, 
increases apoptosis (Finelli et al. 2016). Conversely, over-
expressing Kiaa1609 in neurons was protective (Finelli 
et al. 2016). Thus, KIAA1609 is likely involved in the OS 
response, although its effect—protective or detrimental—
might be organism and cell-type specific.
TLDc proteins as therapeutic targets?
Given the importance of OS in the pathophysiology of 
neurodegenerative disorders (Melo et  al. 2011), strategies 
employing antioxidants have been tested successfully in 
animal models of neurodegenerative diseases (Kim et  al. 
2015; Melo et al. 2011). However, clinical trials based on 
exogenous intake of low-molecular weight compounds 
with antioxidant properties have been only partially suc-
cessful [reviewed in (Kim et  al. 2015)]. For example, in 
early-stage PD, treatment with the monoamine oxidase 
inhibitor selegiline was able to delay the onset of major 
disability (Shoulson 1998), although it did not affect long-
term symptoms nor extend life (Shoulson 1989, 1998). 
This limited success could be due, in part, to the fact that 
the small molecule antioxidants used reduce only one sub-
type of ROS. For example, coenzyme Q specifically targets 
superoxide radicals, but has no effect on the other ROS 
such as hydroxyl radicals, peroxides,  H2O2 or hydroxyl ions 
(Phaniendra et al. 2015). Moreover, free radical scavenging 
alone is unlikely to reverse the established damage to DNA, 
proteins, lipids, and organelles that would have already 
occurred by the time of treatment (Amor et al. 2014).
Thus, to overcome these limitations, it has been sug-
gested that activation of endogenous antioxidant proteins 
that target a range of pathways would be a better approach 
than the use of exogenous compounds (Chan and Chan 
2015). In this context, the identification and characteri-
sation of novel endogenous antioxidant proteins—such 
as those containing a TLDc domain—may be a valuable 
approach for the design new therapeutic strategies against 
neurodegeneration. Importantly, mice over-expressing 
Oxr1 in their CNS have normal phenotype (Liu et al. 2015), 
which demonstrates that increasing OXR1 levels would not 
be detrimental if used as part of a therapeutic strategy. As 
discussed above, over-expression of Oxr1 in  vivo delays 
neurodegenerative phenotypes driven by a reduction in 
OS levels and inflammation (Liu et al. 2015) and intrave-
nous delivery of stably transfected human OXR1 in MSCs 
resulted in a reduction of OS and inflammation in a mouse 
model of lupus nephritis (Li 2014). Thus, there is growing 
evidence that over-expression of OXR1 could be a viable 
and safe clinical approach.
If TLDc-containing proteins show promise as potential 
therapeutic targets, strategies aimed at identifying activity-
modulating compounds are confounded by a limited knowl-
edge of the TLDc domain itself. Although OXR1 appears 
to lack enzymatic activity, recent studies have described the 
importance of highly evolutionary conserved amino-acid 
residues in the TLDc domain that are required for antioxi-
dant capabilities (Finelli et al. 2016). Importantly, to assist 
these studies, the three-dimensional structure of the TLDc 
domain of Ncoa7 from zebrafish has been solved (Blaise 
et al. 2012). These data revealed that the domain consists of 
four alpha-helices and ten beta-strands (Finelli et al. 2016), 
yet it contains no structural similarity to any known pro-
tein folds, providing no clear functional clues (Blaise et al. 
2012). Most recently, the three-dimensional structure of the 
TBC domain from the TBC1D24 Drosophila orthologue 
skywalker (sky) has been described (Fischer et  al. 2016). 
These data revealed a cationic binding pocket for phospho-
inositide phosphorylated at positions 4 and 5 (PI(4,5)PI2 
or PI(3,4,5)PI3) that appear to be structurally distinct from 
other known phosphoinositide binding domains (Fischer 
et al. 2016; Lewis et al. 2011). Furthermore, it was demon-
strated that certain conserved residues mutated in DOORS 
syndrome prevented membrane association of the sky pro-
tein, generating the hypothesis that the resulting increase in 
vesicular trafficking influences synaptic transmission and 
causes the hyperactive phenotype observed in sky mutants 
(Czech 2000; Del Signore and Rodal 2016; Fischer et  al. 
2016). However, it is unknown whether this particular path-
way is significant in disease pathogenesis; in particular, 
the sky mutants studied do not model all known DOORS 
syndrome patients, and overall they represent only a small 
proportion of all TBC1D24-associated mutations that occur 
throughout the protein sequence (Balestrini et  al. 2016). 
Nevertheless, new structural observations such as these are 
an important step towards understanding why mutations 
in TBC1D24 cause such a range of serious neurological 
disorders. Furthermore, deciphering the common molecu-
lar mechanisms that underlie the function of the TLDc 
domain across the TLDc family will benefit research into 
TBC1D24-associated disorders, in addition to the potential 
application of OXR1 up-regulation as future therapeutic 
strategy.
Future directions
Many questions regarding the functions of the TLDc fam-
ily remain unanswered. Here, we have discussed the com-
mon neuroprotective properties of these proteins as con-
ferred by the TLDc domain; however, it is unknown to 
what extent compensatory mechanisms occur when one 
TLDc protein is disrupted. As outlined above, specific 
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isoforms of the TLDc proteins are present in distinct cel-
lular compartments and can be induced by different cel-
lular stimuli; although it is still unclear whether these 
proteins act via similar mechanisms under given cellular 
conditions. For example, could loss-of-function muta-
tions in one TLDc protein be ‘rescued’ by another? Fur-
thermore, are TLDc proteins independent of, or upstream 
of, well-known antioxidant pathways? Future studies are 
certainly required to shed more light on these impor-
tant aspects of functional specificity, commonality and 
redundancy.
The clinical importance of TBC1D24—including 
mutations in the TLDc domain itself—is now well-estab-
lished and there is an obvious need to understand the 
complex functional consequences of pathogenic muta-
tions right across the protein structure. The pleiotropic 
effect of gene disruption is not an uncommon phenom-
enon in neurological disease (Valtorta et  al. 2016), and 
initial mechanistic studies are pointing towards a key role 
for TBC1D24 in vesicle trafficking. Nonetheless, there is 
a need for a more systematic approach in model systems 
to help elucidate the intricacies of genotype and pheno-
type across the spectrum of TBC1D24-associated dis-
ease; in particular, as many more pathogenic mutations 
are likely to be described in the coming years as sequenc-
ing-based diagnoses becomes more routine.
The role of other TLDc proteins in human disease 
remains to be elucidated, although a very recent whole-
exome sequencing study from families with specific lan-
guage impairment (SLI) identified an inherited heterozy-
gous mutation that introduces a premature stop codon 
in the first unique exon of the shortest OXR1 isoform 
(OXR1-C, Fig. 1) (Chen et al. 2017). These data are par-
ticularly intriguing, as it indicates that haploinsufficiency 
for a short TLDc domain-containing isoform leads to a 
neurodevelopmental phenotype. Not only does this find-
ing suggest that the role of OXR1 in early development 
warrants further study, it provides further evidence that 
the subtleties of TLDc domain-containing protein func-
tion will extend to many, as-yet unexplored aspects of 
nervous system biology.
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